3Q26 Revenue and Profit Maintain Growth Momentum
发布时间:2026-11-09 来源:华泰证券
Kanion Pharma's 9M26 revenue/attributable net profit(NP)/recurring NP were RMB2.42/0.21/0.17bn(+3/+6/+6%YoY).The 3Q26 figures were RMB0.76/0.06/0.04bn(+9/+12/+1%YoY).As quarterly revenue and profit continue to recover,we expect 4Q26 to maintain growth momentum.Maintain BUY on the continuous realization of innovative TCM,biological,and chemical drug pipelines.
9M26 pharmaceutical revenue increased by 2%YoY
For 9M26,pharmaceutical revenue increased by 2%YoY to RMB2.37bn(flat YoY in 1H26).Among this,injectables(Reduning,Ginkgolide,etc.)revenue grew by 5%YoY to RMB810mn,with growth slowing down(+24%YoY in 1H26)primarily due to slower implementation of the 4th batch of VBP involving Ginkgolide;oral formulations(Jinzhen,Shenwu Yishen,Guizhi Fuling,Yaobitong,Tianshu,etc.)revenue turned from negative to positive growth(+3%YoY to RMB1.41bn,vs.-8%YoY in 1H26),driven by oral product sales in new retail,OTC,and BD channels;external formulations(Nanxing Zhitong Plaster,Jingu Zhitong,etc.)revenue declined by 14%YoY to RMB160mn,impacted by DRG medical insurance cost controls.With the recovery of the respiratory category,VBP implementation for Ginkgolide(c.20%price decline,landing successively across regions in Sep-Oct),and national Essential Medicines List(nEML)additions(Sanjie Zhentong,etc.),we expect pharmaceutical revenue to maintain growth in 2026-27.
Performance after nEML additions worth expecting
The nEML was updated in July 2026,adding two Chinese patent medicines(with Sanjie Zhentong being exclusive)and five chemical drugs for the company.The National Health Commission issued the Notice on Doing aGood Job in the Priority Provision and Use of Essential Medicines in August,emphasizing that all regions should complete list updates by end-October,while incorporating the proportions of equipped varieties,usage volume,usage amount,and prescriptions into performance evaluation.Benefiting from accelerated hospital admissions and essential medicine evaluations,we believe revenue for Chinese patent medicines entering the list is set to scale up.As amature oral product that has already achieved acertain scale,Sanjie Zhentong(endometriosis)is poised to enter anew round of growth,in our view.
Progress across TCM,chemical,and biological drugs
As of end-October:1)Chinese patent medicines:Four innovative TCM NDAs(Liuwei Dihuang Glycoside Sugar Tablets,Suxin Tongqiao Granules,Shuangyu Granules,Reduning Granules),and six Class 1.1 innovative TCMs approved for clinical trials;2)Chemical drugs:DC20(Alzheimer's disease)entered Phase III clinical trials;SIPI-2011(ventricular arrhythmia),DC042(benign prostatic hyperplasia),WXSH0493(gout),and AAPB(stroke)are in Phase II clinical trials;3)Biological drugs:ZX1305E(neurotrophic keratitis)completed Phase II summary,ZX1305(optic nerve injury treatment)is preparing for Phase IIb trials,ZX2021(overweight or obesity)and ZX2010(Type 2diabetes)are in Phase II trials,while KYS202004A(psoriasis)and KYS202002A(adult systemic lupus erythematosus)are in Phase Itrials.
Maintain BUY
Considering that the fourth quarter is ahigh-demand season for cardiovascular/cerebrovascular and respiratory in-hospital drugs,and is likely to drive full-year revenue and profit growth,we maintain our earnings forecasts,expecting 2026/2027/2028 attributable NP to reach RMB350/400/460mn(+15/+15/+14%YoY).We value the stock at 25x 2027E PE,above its peers'average of 12x on Wind consensus,reflecting the company's high growth potential from increased R&D investments that temporarily impact profit while enriching product reserves,as well as areturn to normalcy after compliance adjustment periods.Our target price is RMB17.68(previous:RMB17.31,based on 2026E attributable NP of RMB350mn and 28x PE).Maintain BUY.
Risks:hospital prescription drug sales pressure exceeding expectations,Zhongxin Pharmaceutical R&D falling short of expectations.